Orbimed Advisors LLC Crinetics Pharmaceuticals, Inc. Put Options Transaction History
Orbimed Advisors LLC
- $2.93 Billion
- Q3 2025
Put Options
1 transactions
Others Institutions Holding CRNX
# of Institutions
248Shares Held
93.6MCall Options Held
695KPut Options Held
80.6K-
Vanguard Group Inc Valley Forge, PA9.17MShares$391 Million0.01% of portfolio
-
Wellington Management Group LLP Boston, MA8.38MShares$358 Million0.06% of portfolio
-
Driehaus Capital Management LLC Chicago, IL6.48MShares$277 Million2.29% of portfolio
-
Black Rock Inc. New York, NY6.23MShares$266 Million0.01% of portfolio
-
Farallon Capital Management LLC San Francisco, CA5.77MShares$246 Million1.04% of portfolio
About Crinetics Pharmaceuticals, Inc.
- Ticker CRNX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 53,752,800
- Market Cap $2.29B
- Description
- Crinetics Pharmaceuticals, Inc., a clinical stage pharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for rare endocrine diseases and endocrine-related tumors. Its lead product candidate is Paltusotine, an oral selective nonpeptide somatostatin receptor type 2 agonist that has completed phase III ...